MannKind moves to accelerate Afrezza growth

US drugmaker MannKind Corp (Nasdaq: MNKD) today announced the launch of a new titration pack containing 60 – 4 unit cartridges, 60 – 8 unit cartridges and 60 – 12 unit cartridges of Afrezza (insulin human) inhalation powder.

This new package is intended to simplify physician prescribing of Afrezza and allow patients greater dose flexibility in managing their diabetes, while potentially reducing the cost burden of multiple co-pays.

Michael Castagna, chief commercial officer of MannKind, stated: “We are excited to see our new Titration Packs entering the supply chain this week. This new titration box along with our new sample program will enable higher dose mealtime insulin patients to dose Afrezza appropriately and manage their disease in as few inhalations as possible.”